Earlier in January, Recursion Pharmaceuticals updated investors at the JP Morgan Healthcare Conference on its AI-powered drug discovery platform, clinical programs, and collaborations with partners ...
Integrated Biosciences has a new Chief Scientific Officer (CSO), naming Daniel J. Anderson, PhD, to the post. Anderson joins ...
Leaders don’t fail from complexity overload. They fail from pretending it’s simple, then engineering systems that move ...
Biotech industry leader joins company as it enters its next phase of growthREDWOOD CITY, Calif.--(BUSINESS WIRE)--#AI--Integrated Biosciences, a biotechnology company combining synthetic biology, ...
Microsoft programs appear to be suffering an outage.
Q4 2025 Earnings Call January 22, 2026 5:00 PM ESTCompany ParticipantsJohn Pitzer - Corporate Vice President of Corporate ...
Explore how real estate tokenization works through smart contract architecture, enabling secure, transparent property ...
The Mila artificial intelligence institute in Quebec is raising a US$100-million venture capital fund with plans to invest in more than 55 early-stage AI companies, in partnership with Inovia Capital ...
Odd News on MSN
Museum of personal failure opens in Vancouver, immediately achieves stated mission for founder
Burnaby man builds monument to romantic collapse; mother contributes wedding dress.
Ricursive joins Recursive and Unconventional AI in raising massive funds at multi-billion valuations out of the gate.
Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results